---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-303393"
form_type: "8-K"
ticker: "RNA"
cik: "0002093101"
company_name: "Atrium Therapeutics, Inc."
filed_at: "2026-07-14T21:14:28+00:00"
generated_at: "2026-07-14T21:16:06.911443+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start

## Summary
- FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.
- Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.
- Initial proof-of-concept data anticipated in second half of 2027.
- PRKAG2 syndrome is a rare genetic cardiomyopathy with no approved therapy addressing root cause.
- This is Atrium's first precision cardiology program to enter clinic.

## SEC filing metadata
- accession: 0001193125-26-303393
- form_type: 8-K
- ticker: RNA
- cik: 0002093101
- company_name: Atrium Therapeutics, Inc.
- filed_at: 2026-07-14T21:14:28+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/0001193125-26-303393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/d132402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-303393
- JSON: https://secwatch.observer/filing/0001193125-26-303393.json
- Plain text: https://secwatch.observer/filing/0001193125-26-303393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.